logo-loader
viewLexaria Bioscience Corp.

Lexaria Bioscience announces optimistic new trial results for its hemp oil capsule TurboCBD

A single 90mg dose of TurboCBD showed evidence of lower blood pressure and higher blood flow to the brain

clinical trial
Lexaria intends to conduct further clinical investigations within the next year using Dehydratech for cannabinoids

Lexaria Bioscience Corp (OTCQX:LXRP) (CSE:LXX) alerted investors on Thursday to a series of optimistic findings from a 2018 European study evaluating TurboCBD, its Dehydratech-powered cannabidiol (CBD) fortified hemp oil capsule.

Results from the study reveal that a single 90mg dose of TurboCBD showed evidence of lower blood pressure; higher blood flow to the brain; faster delivery of CBD into the bloodstream and larger quantities of CBD within the blood when measured against a single 90mg dose of generic CBD.

The study also suggested that Lexaria’s Dehydratech technology allows for better cannabinoid delivery upon ingestion.

READ: Lexaria Bioscience inks deal with Altria Ventures to develop reduced-risk nicotine products; shares soar

As part of the trial 90mg  dose of Lexaria’s TurboCBD was compared to the effects of a 90mg CBD dose without Lexaria’s Dehydratech technology (the positive control) as well as a placebo.

And analysis when CBD was at peak blood levels, thanks to Lexaria’s TurboCBD using DehydraTECH, showed a significant reduction in mean arterial blood pressure (MAP) compared to both the placebo and the generic CBD. This result highlights the usefulness of Lexaria's technology to allow for CBD to reduce blood pressure.

READ: Lexaria Bioscience: The cannabis company developing a potentially life-saving technology

“The findings that Lexaria’s Dehydratech technology can enable superior cannabinoid delivery are unique in this healthy-human clinical trial,” said Dr Phlip Ainslie, principal investigator and co-director of the Centre for Heart, Lung and Vascular Health at UBC Okanagan Campus, Kelowna, Canada. “Establishing the impact of CBD delivery on the health of the circulatory systems, including the brain, could have major implications for the adjunct treatment of high blood pressure and some neurological diseases.”

On the back of the study, Lexaria intends to conduct further clinical investigations within the next year using Dehydratech for cannabinoids with an expanded number of subjects over a more varied age range. Additional data and reports will be provided from future studies as they become available.

Based in Kelowna, British Columbia, Lexaria has developed and licenses out its disruptive delivery technology which increases intestinal absorption rates and offers more rapid delivery to the bloodstream. Dehydratech is essentially a delivery system that allows drugs and vitamins to get into the bloodstream quicker.

Lexaria shares slipped 2% to finish at C$1.94 on Wednesday.

Contact Ellen Kelleher at [email protected] 

Quick facts: Lexaria Bioscience Corp.

Price: 0.63 CAD

CSE:LXX
Market: CSE
Market Cap: $50.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks hold steady; Lexaria rises on amended agreement...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, inched 0.2% higher at 122.9 points. Elsewhere, the OTCQX Cannabis index lost 0.2% to 489.3 points. Buds today are Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), Curaleaf Holdings Inc...

on 22/1/20

2 min read